HPV-Specific Systemic Antibody Responses and Memory B Cells are Independently Maintained up to 6 Years and in a Vaccine-Specific Manner Following Immunization with Cervarix and Gardasil in Adolescent and Young Adult Women in Vaccination Programs in Italy
Authors:
- Francesco NicoliFNFrancesco Nicoli
- Barbara MantelliBMBarbara Mantelli
- Eleonora GalleraniEGEleonora Gallerani
- Valentina TelatinVTValentina Telatin
- Irene BonazziIBIrene Bonazzi
- Peggy MarconiPeggy Marconi
- Riccardo GavioliRGRiccardo Gavioli
- Liliana GabrielliLGLiliana Gabrielli
- Tiziana LazzarottoTLTiziana Lazzarotto
- Luisa BarzonLuisa Barzon
- Giorgio PalùGiorgio Palù
- Antonella CaputoACAntonella Caputo
Open Access
Abstract
Human papillomavirus (HPV) persistent infections are associated with cervical cancer and other HPV-related diseases and tumors. Thus, the characterization of long lasting immunity to currently available HPV vaccines is important. A total of 149 female subjects vaccinated with Cervarix or Gardasil participated to the study and they were stratified according to age (10–12-year-old and 16–20-year-old). Humoral immune responses (IgG and neutralizing antibody titers, antibody avidity) and circulating memory B cells were analyzed after an average of 4–6 years from the third immunization. The humoral responses against HPV-16 and HPV-18 (and HPV-6 and HPV-11 for Gardasil) were high in both age groups and vaccines up to six years from the third dose. However, Cervarix induced significantly higher and more persistent antibody responses, while the two vaccines were rather equivalent in inducing memory B cells against HPV-16 and HPV-18. Moreover, the percentage of subjects with vaccine-specific memory B cells was even superior among Gardasil vaccinees and, conversely, Cervarix vaccinated individuals with circulating antibodies, but undetectable memory B cells were found. Finally, a higher proportion of Cervarix-vaccinated subjects displayed cross-neutralizing responses against non-vaccine types HPV-31 and HPV-45. Gardasil and Cervarix may, thus, differently affect long-lasting humoral immunity from both the quantitative and qualitative point of view.Keywords
This publication has 74 references indexed in Scilit:
- A Review of Clinical Trials of Human Papillomavirus Prophylactic VaccinesVaccine, 2012
- Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individualsMolecular and Cellular Probes, 2012
- Living on Three Time Scales: The Dynamics of Plasma Cell and Antibody Populations Illustrated for Hepatitis A VirusPLOS Computational Biology, 2012
- Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialThe Lancet Oncology, 2012
- Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine seraVaccine, 2011
- End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of ageBritish Journal of Cancer, 2011
- Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young WomenJNCI: Journal of the National Cancer Institute, 2010
- A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital LesionsCancer Prevention Research, 2009
- Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvantCellular and Molecular Life Sciences, 2008
- Toll-like receptor control of the adaptive immune responsesNature Immunology, 2004